Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398

Fernández‐Martínez, Ana B.; Bajo, Ana M.; Valdehíta, Ana; Arenas, María Isabel; Sánchez‐Chapado, Manuel; Carmena, Marı́a J.; Prieto, Juan Carlos

doi:10.1016/j.peptides.2009.09.018

Cited by 23 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, VIP and PACAP analogs have been shown to affect tumor growth in in vitro and in vivo animal tumor models, suggesting that these receptors could be used as novel therapeutic targets or for localization of tumors [116][117][118][119] . The effect of VIP varies with the type of tumor, by either directly promoting tumor growth [76,[120][121][122] , suppressing growth [123] , or promoting its differentiation through VPAC1 receptor signaling [124,125] .…”

Section: Resultsmentioning

confidence: 99%

Vasoactive intestinal peptide signaling axis in human leukemia

Dorsam

Benton²,

Failing³

et al. 2011

WJBC

View full text Add to dashboard Cite

The vasoactive intestinal peptide (VIP) signaling axis constitutes a master "communication coordinator" between cells of the nervous and immune systems. To date, VIP and its two main receptors expressed in T lymphocytes, vasoactive intestinal peptide receptor (VPAC)1 and VPAC2, mediate critical cellular functions regulating adaptive immunity, including arresting CD4 T cells in G1 of the cell cycle, protection from apoptosis and a potent chemotactic recruiter of T cells to the mucosa associated lymphoid compartment of the gastrointestinal tissues. Since the discovery of VIP in 1970, followed by the cloning of VPAC1 and VPAC2 in the early 1990s, this signaling axis has been associated with common human cancers, including leukemia. This review highlights the present day knowledge of the VIP ligand and its receptor expression profile in T cell leukemia and cell lines. Also, there will be a discussion describing how the anti-leukemic DNA binding transcription factor, Ikaros, regulates VIP receptor expression in primary human CD4 T lymphocytes and T cell lymphoblastic cell lines (e.g. Hut-78). Lastly, future goals will be mentioned that are expected to uncover the role of how the VIP signaling axis contributes to human leukemogenesis, and to establish whether the VIP receptor signature expressed by leukemic blasts can provide therapeutic and/or diagnostic information.

show abstract

Section: Resultsmentioning

confidence: 99%

Vasoactive intestinal peptide signaling axis in human leukemia

Dorsam

Benton²,

Failing³

et al. 2011

WJBC

View full text Add to dashboard Cite

show abstract

“…VIP receptors are expressed in a variety of tumors [31]. VIP and PACAP can exert pro-or antitumoral effects depending on the cancer type [14,26,27,[32][33][34][35]. This differential response is also observed in glioma cell lines, where VIP and PACAP can either increase, decrease or have no effect on cell proliferation [16][17][18][20][21][22].…”

Section: Discussionmentioning

confidence: 99%

“…Seventy-three cores of human glioma tissues from grade I to IV and 13 normal brain cores (see Table 1 for case details) were analyzed for VPAC1 and VPAC2 staining both in nuclear and non-nuclear compartments, using the above antibodies raised against the C-terminal sequence of each receptor [26,27]. Fig.…”

Section: Vpac1 and Vpac2 Localization On Human Glioma Tmasmentioning

confidence: 99%

Atypical nuclear localization of VIP receptors in glioma cell lines and patients

Barbarin

Seité

Godet

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…All these effects of VIP in prostate are mediated by transactivation of NF-κB and inhibited by the antioxidant curcumin. Furthermore, curcumin demonstrated anti-tumour activity in androgen deprivation-resistant prostate cancer xenografts [20]. In addition, the neuropeptide induces neuroendocrine differentiation in androgendependent prostate cancer LNCaP cells through protein kinase A (PKA), Ras, mitogen-activated protein kinase (MAPK) and phosphatidyl inositol 3-kinase (PI3-K) [21,22].…”

Section: Introductionmentioning

confidence: 99%